Form 4: Neuronetics CFO Awarded 250,000 Restricted Stock Units

Neuronetics, Inc.'s EVP, CFO, and Treasurer, Steven Pfanstiel, was granted 250,000 restricted stock units vesting over three years.

Summary

• Steven Pfanstiel, EVP, CFO, and Treasurer of Neuronetics, Inc. (STIM), was granted 250,000 Restricted Stock Units (RSUs).
• The transaction date for this acquisition was February 23, 2026.
• Each RSU represents a contingent right to receive one share of the Issuer's common stock.
• The RSUs will vest in three equal annual installments, commencing on February 23, 2027.
• Vesting is contingent upon Mr. Pfanstiel's continuous service to the company through each vesting date.
• Following this transaction, Mr. Pfanstiel beneficially owns 820,212 shares (including these RSUs).

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, primarily reflecting standard executive compensation practices aimed at retaining key talent and aligning management incentives with long-term shareholder value. It does not indicate immediate operational or financial performance changes.

Positives

• The grant of 250,000 RSUs to a key executive like the CFO aligns management's long-term interests with those of shareholders.
• The multi-year vesting schedule (three equal annual installments starting February 23, 2027) acts as a retention mechanism for a critical member of the executive team.
• RSUs are a common form of equity compensation, indicating standard corporate governance practices for executive incentives.

Negatives

• The RSUs have no immediate cash value and their ultimate value depends on the future stock price of Neuronetics, Inc.
• Upon vesting and conversion, these RSUs will result in the issuance of new shares, potentially leading to minor dilution for existing shareholders.
• The 'price' of $0 for the acquisition reflects that these are grants, not purchases, meaning the executive did not invest personal capital directly in this specific transaction.

Risks

• Vesting Conditions: The RSUs are subject to continuous service, meaning Mr. Pfanstiel would forfeit unvested units if he leaves the company before the vesting dates.
• Stock Price Volatility: The ultimate value realized from these RSUs is directly tied to the market price of Neuronetics' common stock at the time of vesting, which can fluctuate.
• Dilution: While common, the issuance of 250,000 new shares upon vesting will slightly dilute the ownership percentage of existing shareholders.

Future Outlook

This RSU grant is a forward-looking incentive designed to retain Steven Pfanstiel and align his interests with the long-term performance of Neuronetics, Inc. The vesting schedule extends through February 2029, indicating a commitment to his continued service.

Industry Context

StockSavvy.ai notes that the grant of Restricted Stock Units (RSUs) to key executives like the CFO is a standard practice in the medical device and technology sectors. This form of equity compensation is widely used to incentivize long-term performance and ensure executive retention, aligning management's financial interests with the company's stock performance over several years.

Comparison to Industry Standards

• RSU grants with multi-year vesting schedules are a common and accepted form of executive compensation across various industries, including medical technology.
• Similar compensation structures are observed at companies like Medtronic (MDT) or Boston Scientific (BSX) for their senior executives, where equity awards are tied to performance and continued service to foster long-term value creation.
• The size of the grant (250,000 units) would typically be evaluated against the executive's role, company size, and peer group compensation benchmarks, though specific peer data is not provided in this filing.

Related Party Transactions

• The RSU grant to Steven Pfanstiel, an executive officer, constitutes a related party transaction, which is a standard form of executive compensation.

Stakeholder Impact

• Shareholders: Potential for long-term alignment of executive interests with shareholder value; minor future dilution upon RSU vesting.
• Employees: Retention of a key executive (CFO) can provide stability and continuity in financial leadership.

Next Steps

• First RSU vesting installment on February 23, 2027.
• Subsequent annual vesting installments on February 23, 2028, and February 23, 2029.

Key Dates

Keywords

Neuronetics, STIM, RSU, Restricted Stock Units, Executive Compensation, Insider Transaction, Form 4